Phase 3 Aloxi (palonosetron, MGI Ph...
Phase 3 Aloxi (palonosetron, MGI Pharma, Inc., Bloomington, MN Helsinn Healthcare SA, Switzerland) trials (99-03 and 99-04) were multicenter, randomized, double-blind, and designed to compare the efficacy and safety profile of palonosetron with that of a comparator agent for prevention of chemotherapy-induced nausea and vomiting (CINV). subdues in study 99-03 were randomized to receive palonosetron (025 mg or 075 mg) or 32 mg ondansetron 30 minutes prior to moderately emetogenic chemotherapy. meditation 99-04 was similarly designed, if it were not that subjects in the comparator arm received
American Football , Real Estate Loans , Voip Service Provers , Palm Beach Real Estate , Conference Calling |